Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel.

IF 5.1 2区医学 Q1 RHEUMATOLOGY

RMD Open Pub Date : 2024-10-23 DOI:10.1136/rmdopen-2024-004727

David Szabo, Alexandra Balogh, Laszlo Gopcsa, Laura Giba-Kiss, Gergely Lakatos, Melinda Paksi, Marienn Reti, Peter Takacs, Pearl van Heteren, Gregor Zadoyan, Silke Holtkamp, Toon Overstijns, Stefan Miltenyi, Peter Remenyi, György Nagy

引用次数: 0

Abstract

We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA, as well as of the subsequent DLBCL that formed the indication of the CAR-T therapy using zamtocabtagene autoleucel, with a 1-year follow-up. According to our best knowledge, this is the first published clinical case report of long-term persisting RA treated with CAR-T cell therapy.

查看原文本刊更多论文

使用zamtocabtagene autoleucel串联CD20-CD19定向非冷冻CAR-T细胞疗法后，伴有弥漫大B细胞淋巴瘤的类风湿性关节炎患者的持续无药缓解。

我们报告了一例长期持续存在的类风湿性关节炎（RA）病例，该病例在伴有弥漫性大 B 细胞淋巴瘤（DLBCL）时接受了 CD20-CD19 CAR-T 治疗，结果之前的类风湿性关节炎和随后的 DLBCL（使用 zamtocabtagene autoleucel 进行 CAR-T 治疗的适应症）均获得了持续的无药缓解，随访期为 1 年。据我们所知，这是第一例发表的使用 CAR-T 细胞疗法治疗长期持续存在的 RA 的临床病例报告。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

RMD Open RHEUMATOLOGY-

CiteScore

7.30

自引率

6.50%

发文量

205

审稿时长

14 weeks

期刊介绍： RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.